Decoy Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
DCOY$1.11+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| Year Ended December 31, 2025 | Year Ended December 31, 2024 | |
|---|---|---|
| Operating activities | ||
| Net loss | $(12,518,480) | $(5,575,777) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation, amortization and impairment | 7,151 | 4,424 |
| Equity-based compensation | 219,058 | 273,730 |
| Change in fair value of warrant liability | (6,540) | — |
| In-process research and development expense | 8,517,966 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 419,628 | 492,471 |
| Accounts payable | (1,167,068) | 334,141 |
| Accrued expenses | (298,903) | (54,326) |
| Net cash used in operating activities | (4,827,188) | (4,525,337) |
| Investing activities | ||
| Issuance of promissory loan in connection with asset acquisition | (577,000) | — |
| Cash received from asset acquisition, net of cash paid | 1,341,735 | — |
| Net cash provided by investing activities | 764,735 | — |
| Financing activities | ||
| Proceeds from issuance of equity securities, net | 12,559,728 | 1,526,460 |
| Payments on note payable | (221,866) | (466,505) |
| Net cash provided by financing activities | 12,337,862 | 1,059,955 |
| Net increase (decrease) in cash, cash equivalents , and restricted cash | 8,275,409 | (3,465,382) |
| Cash, cash equivalents, and restricted cash at beginning of period | 2,434,528 | 5,899,910 |
| Cash, cash equivalents, and restricted cash at end of period | $10,709,937 | $2,434,528 |
| Supplemental cash flow information | ||
| Cash paid for interest | $5,800 | $10,643 |
| Preferred stock issued for in-process research and development technology | 4,302,000 | — |
| Accrued issuance costs for public offering | 185,032 | — |
| Settlement of promissory loans in connection with asset acquisition | 577,000 | — |
| Prepaid expense financed by note payable | — | 398,728 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.